Home Tags Glioblastoma

Tag: Glioblastoma

A&G Pharma and Precision Antibody Identify an Internalizing Target for PTGFRN-positive...

Antibody-drug conjugates (ADC) are effective antibody-based therapeutics for the treatment of cancer and hematological diseases. There is, however, an unmet medical need for the...

Depatuxizumab Mafodotin Did Not Demonstrate Survival Benefit in INTELLANCE-1 Study

Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie, did not demonstrate a survival...

In the War Against Brain Cancer, Accelerated Clinical Trials Are a...

More than 1.4 million people live with malignant brain tumors. Glioblastoma – the cancer that killed Senators John McCain and Ted Kennedy – is...

Study Demonstrates that Targeting EphA3 Expressing Tumor Stem Cells and Neovasculature...

The Eph type-A receptor 3 (also known as EphA3 receptor) is recognized as a functional tumor-specific therapeutic target in glioblastoma (GBM) and is significantly...
Featured Image: Nyhavn, Copenhagen, Denmark. Courtesy: © Fotolia. Used with permission.

University of Copenhagen’s Spin-out company ADCendo to Explore and Commercialize Novel...

Earlier this year spin-out company ADCendo, the University of Copenhagen and the Capital Region of Denmark entered into a worldwide license agreement to develop...

Rare Pediatric Disease Designation for ABT-414 for the Treatment of a...

The U.S. Food and Drug Administration (FDA) has a granted Rare Pediatric Disease Designation for AbbVie's ABT-414, an investigational antibody-drug conjugate (ADC) targeting the...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

Randomized Phase I Trial Results of ABT-414 In Patients with Glioblastoma...

Updated interim results from a Phase I clinical trial of ABT-414 (AbbVie) in patients with glioblastoma multiforme (GBM), an aggressive form of brain cancer,...

Collagen-VI-Alpha-1 is a New Target and a Marker of Poor Outcome...

Functional targeted therapy has unfortunately failed to improve the outcome of glioblastoma patients. While success stories evidenced by the use of antibody-drug conjugates or...
ESMO 2014 Congress - Madrid, Spain

Initial Phase I Trial Results of anti-EGFR drug ABT-414 in the...

With a median survival between 1 and 2 years and no long-term curative treatments, the management of patients with Glioblastoma Multiforme (GBM), the most common and most aggressive type of malignant primary brain tumor, remains challenging.

X